Palliative Care and Oncology Survey on Terminology
ConditionCancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorOur Lady's Hospice and Care Services
About this trial
The term '"cancer survivors" is widely used but has different definitions. One definition describes "cancer survivors" as individuals from the time of diagnosis throughout their lives, which includes people living with cancer and people free of cancer. The views of some groups included in this definition of "cancer survivors" have rarely been assessed, including those with cancer on anticancer treatment and those known to palliative care. How they view these terms could have important implications for how they receive care services.
This is an international multi-centre observational study. It aims to recruit patients internationally across Ireland and the United Kingdom. Participants known to cancer and/or palliative care hospital or hospice services as inpatients, outpatients or community patients will be asked to complete a survey during a one-off visit which should last under 30 minutes. The survey asks a series of questions to determine the perceptions of patients know to cancer and palliative care services about the terminologies used to describe them.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Diagnosis of cancer
Under the care of palliative care services as an inpatient, outpatient or community patient
Age ≥18 years
Able to speak / read English (enough to complete questionnaire)
Disqualifiers
Unable to provide consent
Unable to complete questionnaire
Diagnosis of cancer
Under the care of oncology services and currently receiving an anticancer treatment regimen of any kind
Trial population
Patients known to hospice inpatient units, community palliative care services, hospital palliative care teams and/or oncology services at specified hospices and cancer centres internationally will be invited to participate. Participants may be inpatients, outpatients or community patients associated with the study sites. Participants must meet all of the inclusion criteria for the study, and none of the exclusion criteria for the study. Convenience sampling will be undertaken. Potential participants will be identified by the clinical team. The clinical team will ask them if they would be interested in taking part in a study. If they agree, the research team will arrange to meet with the patient.
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Palliative Care and Oncology Survey on Terminology (POST)
Other interventionEach group receives a survey to complete. The only difference between the two is the inclusion criteria; the surveys are the same.
Treatment groups
1,532 Participants
are divided into 2 treatment groupsGroup A: Group 11 intervention
Group B: Group 21 intervention
Trial outcomes
Primary outcomes
1
The proportion of individuals with cancer known to palliative care services (Group 1) and the proportion of individuals on anti-cancer treatment (Group 2) that would "moderately dislike" or "strongly dislike" being described as a cancer survivor.
The proportion of individuals with cancer throughout the study known to palliative care services (Group 1), and the proportion of individuals with cancer throughout the study on anti-cancer treatment (Group 2), that would "moderately dislike" or "strongly dislike" being described as a cancer survivor. This is not assessing change between two time points in the study, but determining this outcome for the two Groups throughout the whole study.
Time frame
at study completion, an average of 1 yearSecondary outcomes
1
The proportions of these groups (Group 1 and Group 2) that "moderately dislike" or "strongly dislike" being described as a patient, client, consumer, customer, service user, cancer patient, patient with cancer, and person living with cancer.
The proportions of these groups of individuals (Group 1 and Group 2) throughout the study that "moderately dislike" or "strongly dislike" being described as a patient, client, consumer, customer, service user, cancer patient, patient with cancer, and person living with cancer. This is not assessing change between two time points in the study, but determining this outcome for the two Groups throughout the whole study.
Time frame
at study completion, an average of 1 year2
The proportion of these groups (Group 1 and Group 2) that think the specific subgroups of patients with cancer should be known as "cancer survivors":
The proportion of these groups of individuals (Group 1 and Group 2) throughout the study that think the specific subgroups of patients with cancer should be known as "cancer survivors". This is not assessing change between two time points in the study, but determining this outcome for the two Groups throughout the whole study.
Time frame
at study completion, an average of 1 year3
The proportion of these groups (Group 1 and Group 2) that "moderately dislike" or "strongly dislike" the widely used definition of "cancer survivor".
The proportion of these groups of individuals (Group 1 and Group 2) throughout the study that "moderately dislike" or "strongly dislike" the widely used definition of "cancer survivor". This is not assessing change between two time points in the study, but determining this outcome for the two Groups throughout the whole study.
Time frame
at study completion, an average of 1 year4
Any association between perception towards the term cancer survivor and phase of cancer illness, cancer diagnosis and performance status.
Any association between perception towards the term cancer survivor and phase of cancer illness, cancer diagnosis and performance status. This is not assessing change between two time points in the study, but determining this outcome for the participants throughout the whole study.
Time frame
at study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Our Lady's Hospice and Care Services
Lead sponsor
Royal Surrey County Hospital NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov